Pulmonary changes induced by combined mouse β-interferon (rMuIFN-β) and irradiation in normal mice — toxic versus protective effects

Sandra McDonald(Washington University in St. Louis), Philip K. Gregory(University of Rochester), Philip Rubin(University of Bern), David P. Penney(University of Rochester), Richard H. Feins(University of Rochester), Sidney E. Grossberg(Medical College of Wisconsin), Jacob N. Finkelstein(University of Rochester Medical Center), Alex Y. Chang(Cornell University)

Radiotherapy and Oncology

March 1, 1993

10.1016/0167-8140(93)90262-7

Cited by 37

Related Papers

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)

|The Lancet|2005|2.1k

Whole-genome analysis informs breast cancer response to aromatase inhibition

|Nature|2012|1k

Molecular Predictors of Outcome With Gefitinib in a Phase III Placebo-Controlled Study in Advanced Non–Small-Cell Lung Cancer

|Journal of Clinical Oncology|2006|705

Antitumor Activity of Nivolumab in Recurrent and Metastatic Nasopharyngeal Carcinoma: An International, Multicenter Study of the Mayo Clinic Phase 2 Consortium (NCI-9742)

|Journal of Clinical Oncology|2018|473

Chemotherapy, chemoresistance and the changing treatment landscape for NSCLC

|Lung Cancer|2010|441